Headlines about Sangamo Therapeutics (NASDAQ:SGMO) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.1558772327013 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several research analysts have recently commented on the company. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. BidaskClub lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Wells Fargo & Company reiterated an “outperform” rating and issued a $30.00 target price (up previously from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $17.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. Finally, Piper Jaffray Companies set a $8.00 target price on Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Sangamo Therapeutics has an average rating of “Hold” and an average price target of $14.40.

Shares of Sangamo Therapeutics (NASDAQ SGMO) opened at 16.65 on Friday. The company has a 50 day moving average price of $13.31 and a 200 day moving average price of $8.65. The company’s market cap is $1.39 billion. Sangamo Therapeutics has a one year low of $2.65 and a one year high of $17.06.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The firm had revenue of $8.30 million for the quarter, compared to analyst estimates of $5.82 million. During the same period in the previous year, the company posted ($0.38) earnings per share. The company’s quarterly revenue was up 124.3% compared to the same quarter last year. Equities research analysts expect that Sangamo Therapeutics will post ($0.82) earnings per share for the current year.

In other news, VP Curt A. Herberts III sold 11,474 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $10.44, for a total value of $119,788.56. Following the sale, the vice president now directly owns 23,991 shares in the company, valued at approximately $250,466.04. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the sale, the vice president now owns 35,517 shares in the company, valued at $355,170. The disclosure for this sale can be found here. Insiders have sold 87,474 shares of company stock worth $1,169,009 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/sangamo-therapeutics-sgmo-receiving-somewhat-favorable-news-coverage-study-finds/1611794.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.